Transparency vs clarity: the Mifid swaps conundrum

Participants want better OTC transparency, but say Esma’s efforts at clarity could muddy the picture

Sometimes you just can’t do right for doing wrong – and regulators are no exception. As the European Securities and Markets Authority discovered when it tried to clarify Europe’s labyrinthine rules on transparency for over-the-counter derivatives transactions back in 2017. In launching an opinion document that attempted to disambiguate the rules for OTC trade transparency in the second Markets in Financial Instruments Directive, Esma succeeded only in clouding the picture further.

Now, more

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: